BR112016000350A2 - métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica - Google Patents

métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica

Info

Publication number
BR112016000350A2
BR112016000350A2 BR112016000350A BR112016000350A BR112016000350A2 BR 112016000350 A2 BR112016000350 A2 BR 112016000350A2 BR 112016000350 A BR112016000350 A BR 112016000350A BR 112016000350 A BR112016000350 A BR 112016000350A BR 112016000350 A2 BR112016000350 A2 BR 112016000350A2
Authority
BR
Brazil
Prior art keywords
rosacea
methods
pharmaceutical composition
treating inflammatory
inflammatory lesions
Prior art date
Application number
BR112016000350A
Other languages
English (en)
Other versions
BR112016000350A8 (pt
Inventor
Jean Jacovella
Michel Poncet
Jean-Paul Chappuis
Wagner Nathalie Sordello
Alexandre Kaoukhov
Michael Graeber
Laurence Salin
Philippe Briantais
Khaled Benkali
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52133217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016000350(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of BR112016000350A2 publication Critical patent/BR112016000350A2/pt
Publication of BR112016000350A8 publication Critical patent/BR112016000350A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J9/00—Feeding-bottles in general
    • A61J9/06—Holders for bottles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
BR112016000350A 2013-07-08 2014-07-08 métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica BR112016000350A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843540P 2013-07-08 2013-07-08
US201361919208P 2013-12-20 2013-12-20
US201461927717P 2014-01-15 2014-01-15
US14/209,927 US9233117B2 (en) 2013-07-08 2014-03-13 Treatment of inflammatory lesions of rosacea with ivermectin
PCT/US2014/045717 WO2015006305A1 (en) 2013-07-08 2014-07-08 Treatment of inflammatory lesions of rosacea with ivermectin

Publications (2)

Publication Number Publication Date
BR112016000350A2 true BR112016000350A2 (pt) 2017-07-25
BR112016000350A8 BR112016000350A8 (pt) 2020-01-07

Family

ID=52133217

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112016000335A BR112016000335A8 (pt) 2013-07-08 2014-07-08 método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
BR112016000350A BR112016000350A8 (pt) 2013-07-08 2014-07-08 métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112016000335A BR112016000335A8 (pt) 2013-07-08 2014-07-08 método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica

Country Status (17)

Country Link
US (12) US9233117B2 (pt)
EP (2) EP3019173A1 (pt)
JP (7) JP2016526572A (pt)
KR (2) KR101864799B1 (pt)
CN (4) CN111494399A (pt)
AU (2) AU2014287408B2 (pt)
BR (2) BR112016000335A8 (pt)
CA (2) CA2916668A1 (pt)
CL (2) CL2016000008A1 (pt)
HK (2) HK1223841A1 (pt)
IL (3) IL243314B (pt)
MX (2) MX2016000121A (pt)
NZ (2) NZ716034A (pt)
RU (2) RU2633481C2 (pt)
SG (2) SG11201510635PA (pt)
WO (2) WO2015006305A1 (pt)
ZA (1) ZA201600358B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2669942C1 (ru) 2013-11-29 2018-10-17 Галдерма Са Соединение семейства авермектина или семейства мильбемицина для лечения и/или профилактики атопического дерматита
FR3032616B1 (fr) 2015-02-12 2017-02-24 Galderma Sa Compose de la famille des avermectines pour le traitement et/ou la prevention des folliculites
EP3377063B1 (en) 2015-11-17 2023-08-09 Galderma S.A. Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea
AU2017305853B2 (en) * 2016-08-04 2023-04-13 Galderma Holding SA Compositions and the use thereof for treating or preventing rosacea
CN106397233A (zh) * 2016-08-26 2017-02-15 南通奥凯生物技术开发有限公司 一种医药级乙二胺四乙酸二钠的制备方法
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
BR112020012018A2 (pt) 2017-12-15 2020-11-24 Tarsus Pharmaceuticals, Inc. formulações de parasiticida de isoxazolina e métodos para tratar blefarite
US11090352B2 (en) 2019-02-18 2021-08-17 Mary Kay Inc. Topical skin compositions for treating rosacea and skin redness
CN111728959B (zh) * 2020-08-11 2023-02-03 黑龙江天龙药业有限公司 一种抑制油脂分泌且清螨虫的鼻膜贴及其制备方法
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations
WO2022269665A1 (ja) * 2021-06-21 2022-12-29 マルホ株式会社 外用剤
KR102346125B1 (ko) 2021-10-15 2022-01-03 (주)나비바이오텍 이버멕틴 정성 검사용 래피드 키트

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197796A (en) 1980-08-04 1984-11-09 Merck & Co Inc Stabilised aqueous formulations containing ivermectin
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5656280A (en) 1994-12-06 1997-08-12 Helene Curtis, Inc. Water-in-oil-in-water compositions
FR2754452B1 (fr) 1996-10-11 2003-02-14 Oreal Emulsion h/e a forte teneur en electrolytes et leur utilisation en dermo-cosmetique, notamment pour traiter les phenomenes d'irritation et/ou de peaux sensibles
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
FR2787322B1 (fr) 1998-12-18 2002-10-18 Galderma Res & Dev Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie
US6133310A (en) 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6399652B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
US6399651B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US6319945B1 (en) 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
DE10063946A1 (de) 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
CA2473760C (en) 2002-02-08 2008-11-04 Merck & Co., Inc. Topical ivermectin composition
CA2478589A1 (en) 2002-03-04 2003-09-18 Divergence, Inc. Nematicidal fatty acid and fatty acid ester related compounds
FR2854074B1 (fr) * 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
AU2004231323C1 (en) * 2003-04-24 2016-11-03 Galderma Holding SA Topical formulation of ivermectin for the treatment of dermatological conditions
EP1600158A1 (en) 2004-05-26 2005-11-30 Galderma Research & Development, S.N.C. Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2883181B1 (fr) 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886852B1 (fr) 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2886851B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2886850B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2894823B1 (fr) 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907013B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
JP2012513387A (ja) 2008-12-23 2012-06-14 ガルデルマ・ソシエテ・アノニム 感水性の活性成分を含む、局所用医薬組成物
JP2012516320A (ja) 2009-01-30 2012-07-19 イッスム リサーチ デベロプメント カンパニー オブ ザ ヘブライ ユニバーシティ オブ エルサレム リミテッド 爪および皮膚を処置するための組成物
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee

Also Published As

Publication number Publication date
IL274058A (en) 2020-06-30
EP3019174A1 (en) 2016-05-18
RU2633481C2 (ru) 2017-10-12
US20220347198A1 (en) 2022-11-03
NZ716033A (en) 2017-01-27
IL243314A0 (en) 2016-02-29
JP6653734B2 (ja) 2020-02-26
JP2018184437A (ja) 2018-11-22
HK1223841A1 (zh) 2017-08-11
CA2916668A1 (en) 2015-01-15
US20160184342A1 (en) 2016-06-30
SG11201510420UA (en) 2016-01-28
US20200000835A1 (en) 2020-01-02
KR20160061310A (ko) 2016-05-31
NZ716034A (en) 2017-01-27
JP6438466B2 (ja) 2018-12-12
US10206939B2 (en) 2019-02-19
JP2023052490A (ja) 2023-04-11
US20160143935A1 (en) 2016-05-26
US20180264021A1 (en) 2018-09-20
BR112016000335A2 (pt) 2017-07-25
EP3019173A1 (en) 2016-05-18
WO2015006305A1 (en) 2015-01-15
KR101864799B1 (ko) 2018-06-05
RU2633076C2 (ru) 2017-10-11
JP2017197562A (ja) 2017-11-02
CL2016000008A1 (es) 2016-08-05
CN111494399A (zh) 2020-08-07
AU2014287408A1 (en) 2016-02-11
SG11201510635PA (en) 2016-01-28
HK1223842A1 (zh) 2017-08-11
US20160175337A1 (en) 2016-06-23
CN105792829A (zh) 2016-07-20
AU2014287408B2 (en) 2017-05-04
IL274058B (en) 2022-02-01
IL243315A0 (en) 2016-02-29
AU2014287422A1 (en) 2016-02-11
AU2014287422B2 (en) 2017-04-13
MX2016000121A (es) 2016-07-14
US20180207188A1 (en) 2018-07-26
US20210177882A1 (en) 2021-06-17
KR101863085B1 (ko) 2018-06-01
MX2016000122A (es) 2016-06-15
BR112016000350A8 (pt) 2020-01-07
RU2016103753A (ru) 2017-08-11
US20150011490A1 (en) 2015-01-08
JP2016523968A (ja) 2016-08-12
US9233117B2 (en) 2016-01-12
IL243314B (en) 2022-02-01
JP2021059590A (ja) 2021-04-15
CL2016000009A1 (es) 2016-08-19
CA2916704A1 (en) 2015-01-15
CA2916704C (en) 2018-11-20
WO2015006319A1 (en) 2015-01-15
CN105828825A (zh) 2016-08-03
ZA201600358B (en) 2019-11-27
JP2019073527A (ja) 2019-05-16
KR20160061311A (ko) 2016-05-31
US20150011491A1 (en) 2015-01-08
US20150011489A1 (en) 2015-01-08
RU2016103715A (ru) 2017-08-11
BR112016000335A8 (pt) 2020-01-07
CN111467301A (zh) 2020-07-31
US9233118B2 (en) 2016-01-12
US20180177813A1 (en) 2018-06-28
JP2016526572A (ja) 2016-09-05
IL243315B (en) 2022-02-01
US9089587B2 (en) 2015-07-28

Similar Documents

Publication Publication Date Title
BR112016000350A2 (pt) métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica
FR21C1059I2 (fr) Compositions pharmaceutiques
HK1220980A1 (zh) 用於治療龐貝氏症的方法和組合物
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
EP2981611A4 (en) ANTIBIOTICUM PROTOCOLS AND PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THEREWITH
IL239735B (en) A pharmaceutical preparation for the treatment of diseases related to toxic aldehyde
ES2966571T3 (es) Biogénesis de miARN en exosomas para diagnóstico y terapia
DK3049056T3 (da) Topisk antisvampesammensætning og fremgangsmåder til behandling
HK1218621A1 (zh) 用於治療慢性炎症和炎性疾病的組合物及方法
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
CL2015002146A1 (es) Composiciones y procedimientos para tratar heridas superficiales
BR112015028115A2 (pt) métodos e composições para o tratamento de câncer
DK3098224T3 (da) Pyranochromenyl-phenolderivat og farmaceutisk sammensætning til behandling af metabolisk syndrom eller inflammationssygdom
CL2015002866A1 (es) Tratamiento de fibrosis e inflamación mediante la inhibición de tl1a
DK3079655T3 (da) Inhalerbare lægemidler
EA033123B9 (ru) Антипролиферативная и антиметастатическая фармацевтическая композиция и способ лечения рака
DK3369435T3 (da) Sammensætning til behandling af inflammatorisk ledsygdom
DK3003401T3 (da) Farmaceutisk præparat
BR112015023621A2 (pt) derivados de menopenem e usos dos mesmos
HK1204916A1 (en) Pharmaceutical application of anhydroicaritin
DK2897588T3 (da) Inhalerbart lægemiddel
DK2964623T3 (da) Substituerede chroman-6-yloxycycloalkaner og deres anvendelse som farmaceutik
BR112014017217A8 (pt) agente e composição farmacêutica
EP3046629A4 (en) Treatment of inflammatory skin disease
FR3022461B1 (fr) Methodes therapeutiques et compositions

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: GALDERMA HOLDING SA (CH)